Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: RedirecTT-1 Follow-Up

Opinion
Video

Panelists discuss how the follow-up results from the RedirecTT-1 study provide insights into the long-term efficacy and safety of bispecific antibody combinations in treating relapsed/refractory multiple myeloma, potentially shaping future treatment approaches for this challenging disease.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content